Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29518008 | 1.00 | HTR2B (0.66) | HTR2BPDE4DALDH1A1RXFP1PTPN11 | |
| SCHEMBL8412370 | 0.87 | HTR2B (0.83) | HTR2BPDE4DALDH1A1RXFP1RAB9A | |
| SCHEMBL10642190 | 0.83 | AHR (0.47) | HTR2BPDE4DALDH1A1RAB9ATP53 | |
| SCHEMBL4359675 | 0.79 | AGPAT2 (0.48) | HTR2BPDE4DALDH1A1RAB9AIDO1 | |
| Irsogladine SCHEMBL62215 | 0.79 | HTR2B (1.00) | HTR2BPDE4DALDH1A1RXFP1RAB9A | |
| Irsogladine SCHEMBL29517870 | 0.79 | HTR2B (1.00) | HTR2BPDE4DALDH1A1RXFP1RAB9A | |
| SCHEMBL19937094 | 0.76 | HTR2B (0.58) | HTR2BPDE4DALDH1A1RXFP1PTPN11 | |
| SCHEMBL29364307 | 0.75 | TP53 (0.61) | HTR2BPDE4DALDH1A1RXFP1PTPN11 | |
| SCHEMBL440944 | 0.75 | TP53 (0.61) | HTR2BPDE4DALDH1A1RXFP1PTPN11 | |
| SCHEMBL19937092 | 0.75 | HTR2B (0.56) | HTR2BPDE4DALDH1A1TP53ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478414-A | Novel synthesis process method of gastric mucosa protective medicine | 苏州虞美景盛新药开发有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-7618968-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7291616-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2003-08-14 | — | — | US | disclosed |
| WO-2003037346-A1 | 6-PHENYL-N-PHENYL-(1,3,5) -TRIAZINE-2,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOPHPHOSPHATIDIC ACID ACYLTRANSFERASE BETA (LPAAT-BETA) INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-0066799-B1 | NICOTINIC ACID DERIVATIVES | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1986-01-02 | — | — | EP | disclosed |
| US-4415570-A | TREATMENT FOR RHEMATIC DISEASES AND ALLERGIC NEPHRYTIS; UROGENITAL DISORDERS | NIPPON SHINYAKU CO. LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
| EP-0066799-A2 | Nicotinic acid derivatives | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1982-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | HTR2B 2836/4885PDE4D 1977/4885ALDH1A1 1286/4885 |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | HTR2B 2043/4885PDE4D 1187/4885ALDH1A1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.